Sign Up to like & get
recommendations!
0
Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps5-10
Abstract: Background: CDK4/6 inhibitors have emerged as the standard of care for HR+ MBC. However, there is limited insight into the potential benefit of abemaciclib following prior progression on palbociclib or ribociclib. Based on a multi-center…
read more here.
Keywords:
following prior;
progression palbociclib;
progression;
cancer ... See more keywords